US10406240 — PSMA binding ligand-linker conjugates and methods for using
Method of Use · Assigned to Purdue Research Foundation · Expires 2028-08-15 · 2y remaining
What this patent protects
This patent protects methods for using PSMA binding ligand-linker conjugates, including pharmaceutical compositions containing them, for delivering therapeutic, diagnostic, and imaging agents.
USPTO Abstract
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4169 |
— | lutetium-lu-177-vipivotide-tetraxetan |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.